Medigen Vaccine Biologics (6547) — Cash Flow Reinvestment Rate
Medigen Vaccine Biologics (6547) has a Cash Flow Reinvestment Rate of 3.00x as of December 2025, reinvesting NT$303.54 Million (capex NT$3.54 Million plus investments NT$300.00 Million) from operating cash flow of NT$101.08 Million. Explore Medigen Vaccine Biologics (6547) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Medigen Vaccine Biologics Cash Flow Reinvestment Rate (2015–2024)
Historical reinvestment intensity for Medigen Vaccine Biologics across 3 annual periods. Also explore Medigen Vaccine Biologics asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Medigen Vaccine Biologics (2015–2024)
Year-by-year capital reinvestment analysis for Medigen Vaccine Biologics. For live market cap and broader valuation context, see Medigen Vaccine Biologics market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 26.64x | NT$1.09 Billion | NT$40.75 Million | NT$34.98 Million | ▲ +1419.1% |
| 2021 | 1.75x | NT$1.02 Billion | NT$579.89 Million | NT$134.97 Million | ▼ -17.1% |
| 2015 | 2.11x | NT$457.15 Million | NT$216.26 Million | NT$457.15 Million | — |